TrialThe Journal of dermatology2017

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.

Mamitaro Ohtsuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.